NeoGenomics (NASDAQ:NEO) Updates FY 2024 Earnings Guidance

NeoGenomics (NASDAQ:NEO) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.080-0.100 for the period, compared to the consensus earnings per share estimate of 0.060. The company issued revenue guidance of $655.0 million-$667.0 million, compared to the consensus revenue estimate of $661.7 million.

Analysts Set New Price Targets

Several brokerages have commented on NEO. Benchmark restated a “buy” rating and set a $18.00 target price on shares of NeoGenomics in a research report on Tuesday, September 24th. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Wednesday. Finally, Stephens reiterated an “overweight” rating and issued a $19.00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, NeoGenomics currently has a consensus rating of “Moderate Buy” and an average target price of $19.89.

NeoGenomics Trading Up 3.5 %

NASDAQ:NEO traded up $0.53 on Wednesday, reaching $15.46. The stock had a trading volume of 1,244,304 shares, compared to its average volume of 770,070. The company has a market cap of $1.98 billion, a price-to-earnings ratio of -24.94 and a beta of 1.19. NeoGenomics has a 12-month low of $12.77 and a 12-month high of $21.22. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93. The firm’s fifty day moving average is $14.71 and its two-hundred day moving average is $14.73.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.